Metastatic Hormone-Sensitive Prostate Cancer

William K. Oh, MD


September 09, 2019

Metastatic hormone-sensitive prostate cancer (mHSPC) is deadly, with a reported median survival of less than 5 years. Historically, androgen deprivation therapy (ADT) has been the standard of care. The development of new therapeutic options, however, has significantly improved survival.

In this ReCAP, Dr William Oh discusses the essential role that ADT still plays in mHSPC, the importance of recently approved chemoimmunotherapies and small-molecule androgen inhibitors, and how to choose the most appropriate treatment strategy for patients.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.